RESUMO
OBJECTIVE: To describe a case of esophageal ulcer associated with the use of alendronate. CASE REPORT: This is the fifth case ever described in the literature according to our bibliographic review. In our patient, the association between the drug and the esophageal lesions was masked by the presence of a hiatal hernia, potentially a cause of the esophageal lesion. The persistence of the lesions despite high doses of anti-reflux therapy called attention to the possibility of the relationship. The esophageal lesion healed soon after suspension of alendronate. DISCUSSION: The authors present a review of the literature and point to the need for diagnostic investigation, to suspend such a drug from patients who experience dyspeptic symptoms while using it.
Assuntos
Alendronato/efeitos adversos , Doenças do Esôfago/induzido quimicamente , Úlcera/induzido quimicamente , Diagnóstico Diferencial , Doenças do Esôfago/diagnóstico , Feminino , Refluxo Gastroesofágico/diagnóstico , Hérnia Hiatal/diagnóstico , Humanos , Pessoa de Meia-Idade , Úlcera/diagnósticoRESUMO
Patients with positive serum HBAg reactions were treated with Viramid (1-beta-D-ribofuranozyl-1, 2, 4-triazol-3-carboxamide) a new anti-viral drug. Of the patients involved in this study, 5 had chronic hepatitis or prolonged hepatitis and 12 were healthy HBAg carriers. Results obtained suggest that the drug had some action on serum HBAg titres with a decrease or negativation of HBAg serum titres in peripheric blood, the evaluation of which was immediately seen by employing the counterimmune electrophoresis technique.